Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Sequenom: fabrication of diagnostic test results self distructs the company

|Includes: Sequenom, Inc. (SQNM)

Shares are down 37% today -- and down more than 80% this year -- after the vendor of medical-diagnostic tests revealed that flawed research would cause it to throw away years of work.  This is the product of bad "methodology and design" of research testing as well as an intent to committ fraud.

Could the company be a buyout target by a large biotech?  Buying shares at 3.42 and writing Oct strike 4 calls for a .20/contract premium is not a terrible risk. 

Disclaimer: MD Capital Management does not own SQNM